Eton Pharmaceuticals raises 2026 revenue guidance to $120M following 73% Q1 growth driven by multiple product launches and label...

LYMPHIR launches with $36.5M financing secured. The cutaneous T-cell lymphoma drug generated $5.6M in early revenue with near-perfect reimbursement...

ARS Pharmaceuticals' neffy growth hinges on CVS Caremark formulary decision expected in early June 2026, with coverage critical to...

Senti Biosciences identifies Donor X attribute driving SENTI-202 efficacy in relapsed/refractory AML, enabling quality-controlled manufacturing for future produ

FDA approval of once-weekly insulin icodec-abae (Awiqli) gives Novo Nordisk a differentiated basal insulin, but peak sales of $1.2B...

Telix partners with EDAP TMS and Profound Medical to integrate PSMA-PET imaging into minimally invasive prostate cancer treatment workflows.

Citius Oncology reports $5.6M LYMPHIR revenue in first six months of commercial launch, with zero reimbursement denials across covered...

Eton Pharmaceuticals Q1 2026 sales rose 73% to $24.3M, prompting a $10M upward revision to full-year guidance above $120M.

ARS Pharmaceuticals awaits CVS Caremark formulary decision in June that could unlock unrestricted commercial access for neffy.

Senti Biosciences advances SENTI-202 to pivotal trial in relapsed/refractory AML with FDA approval of single-arm design based on Phase...